Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.

Emilio Bajetta(Fondazione Lanza), Giorgio Parmiani(Fondazione IRCCS Istituto Nazionale dei Tumori), A Borri, Ashok Rakhit, Roberta Mortarini(Scripps Research Institute), Lorenza Rimassa(Humanitas University), Camilla Fowst(Inserm), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), R Nadeau, Andrea Anichini(Fondazione IRCCS Istituto Nazionale dei Tumori)
PubMed
January 1, 1998
Cited by 165

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k